FDA launches Neuroscience Advancement and Innovation Nexus to boost brain disorder drug development

The U.S. Food and Drug Administration announced a new program called the Neuroscience Advancement and Innovation Nexus (NAIN) aimed at accelerating the development of medical products for brain and nervous system conditions. The initiative aligns with the administration’s broader effort to speed health care innovation.

NAIN will focus on improving scientific tools and regulatory pathways needed for neuroscience therapies. Its inaugural effort, the Alzheimer’s Prevention Accelerator, seeks to advance products that can delay or prevent Alzheimer’s disease and supports the National Alzheimer’s Project Act.

Acting FDA Commissioner Kyle Diamantas said the program demonstrates the agency’s commitment to keep regulatory science in step with rapid advances in neuroscience and to tackle one of the most pressing public health challenges.